Zacks: Brokerages Set $20.50 Target Price for Simulations Plus, Inc. (SLP)
Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price objective of $20.50 for the company and are expecting that the company will post $0.06 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Simulations Plus an industry rank of 90 out of 255 based on the ratings given to its competitors.
Several equities research analysts have issued reports on the company. BidaskClub raised Simulations Plus from a “hold” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered Simulations Plus from a “buy” rating to a “hold” rating in a research note on Wednesday, September 19th. Finally, ValuEngine lowered Simulations Plus from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 11th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its stake in shares of Simulations Plus by 94.3% in the 1st quarter. Wells Fargo & Company MN now owns 33,093 shares of the technology company’s stock valued at $488,000 after acquiring an additional 16,065 shares during the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of Simulations Plus in the 2nd quarter valued at about $129,000. TIAA FSB bought a new stake in shares of Simulations Plus in the 2nd quarter valued at about $225,000. Stanley Laman Group Ltd. lifted its stake in shares of Simulations Plus by 11.0% in the 2nd quarter. Stanley Laman Group Ltd. now owns 68,585 shares of the technology company’s stock valued at $1,526,000 after acquiring an additional 6,812 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Simulations Plus in the 2nd quarter valued at about $507,000. 35.70% of the stock is owned by institutional investors.
SLP stock traded down $0.45 during mid-day trading on Friday, hitting $20.12. 43,600 shares of the stock were exchanged, compared to its average volume of 64,036. Simulations Plus has a 12 month low of $14.25 and a 12 month high of $23.95. The firm has a market cap of $367.79 million, a P/E ratio of 58.29 and a beta of -0.81.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Read More: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.